• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis.多西他赛和顺铂诱导化疗放疗后手术治疗伴有纵隔淋巴结转移的非小细胞肺癌的长期疗效
Interact Cardiovasc Thorac Surg. 2012 May;14(5):565-9. doi: 10.1093/icvts/ivs028. Epub 2012 Feb 20.
2
Induction chemoradiotherapy is superior to induction chemotherapy for the survival of non-small-cell lung cancer patients with pathological mediastinal lymph node metastasis.对于有病理纵隔淋巴结转移的非小细胞肺癌患者,诱导放化疗在生存方面优于诱导化疗。
Interact Cardiovasc Thorac Surg. 2012 Dec;15(6):954-60. doi: 10.1093/icvts/ivs412. Epub 2012 Sep 12.
3
Chemoradiation Therapy Followed by Surgery in the Treatment of Locoregionally Advanced Non-Small Cell Lung Cancer.同步放化疗后手术治疗局部晚期非小细胞肺癌
Thorac Cardiovasc Surg. 2018 Mar;66(2):129-134. doi: 10.1055/s-0037-1606832. Epub 2017 Oct 9.
4
Combined treatment modalities in Pancoast tumor: results of a monocentric retrospective study.潘科斯特瘤的联合治疗模式:一项单中心回顾性研究的结果
Chin Clin Oncol. 2015 Dec;4(4):39. doi: 10.3978/j.issn.2304-3865.2015.12.01.
5
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).一项多中心II期研究,评估多西他赛和顺铂作为手术或多西他赛同步放化疗前的新辅助诱导方案,随后对II期、IIIA期和IIIB期非小细胞肺癌初治患者进行辅助多西他赛治疗(TAX-AT 1.203试验)。
Lung Cancer. 2014 Sep;85(3):395-400. doi: 10.1016/j.lungcan.2014.06.019. Epub 2014 Jul 3.
6
Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935.非小细胞肺癌病理ⅢA期(N2)三联疗法后的疾病失败模式。癌症与白血病B组方案8935分析。
Cancer. 1996 Jun 1;77(11):2393-9. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2393::AID-CNCR31>3.0.CO;2-Q.
7
Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.接受诱导治疗和手术切除的伴有淋巴结受累的非小细胞肺癌的治疗结果及预后因素
Interact Cardiovasc Thorac Surg. 2014 Aug;19(2):256-62; discussion 262. doi: 10.1093/icvts/ivu141. Epub 2014 May 13.
8
Concomitant chemoradiotherapy with cisplatin and docetaxel followed by surgery and consolidation chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.不能切除的局部晚期非小细胞肺癌患者采用顺铂和多西他赛同步放化疗,然后手术和巩固化疗。
Med Oncol. 2010 Mar;27(1):152-7. doi: 10.1007/s12032-009-9186-z. Epub 2009 Feb 26.
9
Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer.非小细胞肺癌根治性放疗(>59 Gy)及同步化疗后的肺切除术
Ann Thorac Surg. 2004 Oct;78(4):1200-5; discussion 1206. doi: 10.1016/j.athoracsur.2004.04.085.
10
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.多西他赛-顺铂新辅助化疗后纵隔淋巴结清扫对IIIA期pN2非小细胞肺癌患者的生存具有预后价值:一项多中心II期试验
J Clin Oncol. 2003 May 1;21(9):1752-9. doi: 10.1200/JCO.2003.11.040.

引用本文的文献

1
Prophylactic effect of tissue flap in the prevention of bronchopleural fistula after surgery for lung cancer.组织瓣在肺癌术后预防支气管胸膜瘘中的预防作用。
Surg Today. 2025 Mar;55(3):405-413. doi: 10.1007/s00595-024-02927-6. Epub 2024 Aug 28.
2
Predictive Value of PERCIST for Locally Advanced Non-Small Cell Lung Cancer Treated with Preoperative Induction Therapy - A Multicenter Study in Japan.PERCIST对接受术前诱导治疗的局部晚期非小细胞肺癌的预测价值——日本的一项多中心研究
Cancer Manag Res. 2024 Jul 30;16:965-976. doi: 10.2147/CMAR.S464265. eCollection 2024.
3
Identifying optimal surgical approach among T1N2-3M0 non-small cell lung cancer patients: a population-based analysis.确定T1N2-3M0期非小细胞肺癌患者的最佳手术方式:一项基于人群的分析。
Transl Lung Cancer Res. 2024 Apr 29;13(4):901-929. doi: 10.21037/tlcr-24-213. Epub 2024 Apr 25.
4
Impact of the neutrophil-to-lymphocyte ratio on patients with locally advanced non-small cell lung cancer who suffer radiation pneumonitis during the course of induction chemoradiotherapy followed by surgery.中性粒细胞与淋巴细胞比值对接受诱导放化疗联合手术治疗的局部晚期非小细胞肺癌患者放射性肺炎的影响。
Surg Today. 2024 Sep;54(9):995-1004. doi: 10.1007/s00595-024-02816-y. Epub 2024 Mar 7.
5
Lobectomy Versus Sublobectomy in Stage IIIA/N2 Non-Small Cell Lung Cancer: A Population-Based Study.ⅢA/N2期非小细胞肺癌肺叶切除术与肺段切除术的基于人群的研究
Front Oncol. 2021 Dec 9;11:726811. doi: 10.3389/fonc.2021.726811. eCollection 2021.
6
A PET/CT volumetric parameter predicts prognosis of non-small cell lung cancer treated using preoperative chemoradiotherapy and surgery: A retrospective case series study.一项PET/CT容积参数预测术前放化疗联合手术治疗的非小细胞肺癌预后的回顾性病例系列研究。
Mol Clin Oncol. 2021 Apr;14(4):73. doi: 10.3892/mco.2021.2235. Epub 2021 Feb 23.
7
Dose-volume parameters predict radiation pneumonitis after induction chemoradiotherapy followed by surgery for non-small cell lung cancer: a retrospective analysis.剂量-体积参数预测诱导放化疗后手术治疗非小细胞肺癌后放射性肺炎:一项回顾性分析。
BMC Cancer. 2019 Nov 26;19(1):1144. doi: 10.1186/s12885-019-6359-9.
8
Clinical outcome of patients with recurrent non-small cell lung cancer after trimodality therapy.多模式治疗后复发性非小细胞肺癌患者的临床结局。
Surg Today. 2019 Jul;49(7):601-609. doi: 10.1007/s00595-019-1774-8. Epub 2019 Feb 8.
9
Is Surgery after Chemoradiotherapy Feasible in Lung Cancer Patients with Superior Vena Cava Invasion?放化疗后手术对伴有上腔静脉侵犯的肺癌患者是否可行?
Ann Thorac Cardiovasc Surg. 2018 Jun 20;24(3):131-138. doi: 10.5761/atcs.oa.18-00027. Epub 2018 Apr 20.
10
Stromal PDGFR-β Expression is Associated with Postoperative Survival of Non-Small Cell Lung Cancer Patients Receiving Preoperative Chemo- or Chemoradiotherapy Followed by Surgery.基质PDGFR-β表达与接受术前化疗或放化疗后手术的非小细胞肺癌患者的术后生存率相关。
World J Surg. 2018 Sep;42(9):2879-2886. doi: 10.1007/s00268-018-4560-7.

本文引用的文献

1
Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007.局部晚期非小细胞肺癌中多西他赛和顺铂联合化疗与丝裂霉素、长春碱和顺铂联合化疗联合同期胸部放疗的 III 期临床试验:OLCSG 0007。
J Clin Oncol. 2010 Jul 10;28(20):3299-306. doi: 10.1200/JCO.2009.24.7577. Epub 2010 Jun 7.
2
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.III期非小细胞肺癌的放疗联合化疗(无论是否进行手术切除):一项III期随机对照试验
Lancet. 2009 Aug 1;374(9687):379-86. doi: 10.1016/S0140-6736(09)60737-6. Epub 2009 Jul 24.
3
Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial.对部分ⅢB期非小细胞肺癌患者先进行新辅助化疗和放疗,然后进行手术:一项多中心Ⅱ期试验。
Lancet Oncol. 2009 Aug;10(8):785-93. doi: 10.1016/S1470-2045(09)70172-X. Epub 2009 Jul 13.
4
The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.国际肺癌研究协会肺癌分期项目:关于在即将出版的(第七版)《恶性肿瘤TNM分类》中修订TNM分期分组的建议。
J Thorac Oncol. 2007 Aug;2(8):706-14. doi: 10.1097/JTO.0b013e31812f3c1a.
5
Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer.对于体积较大的cN2、N3期非小细胞肺癌,采用诱导放化疗(卡铂-紫杉烷联合50 Gy同步放疗)。
J Thorac Cardiovasc Surg. 2007 May;133(5):1179-85. doi: 10.1016/j.jtcvs.2006.12.039.
6
Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer.多西他赛巩固治疗用于不可切除的 III 期非小细胞肺癌患者,这些患者接受了顺铂、长春瑞滨及同步胸部放疗。
J Thorac Oncol. 2006 Oct;1(8):810-5.
7
Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.IIIA-N2期非小细胞肺癌诱导化疗后手术切除与放射治疗的随机对照试验
J Natl Cancer Inst. 2007 Mar 21;99(6):442-50. doi: 10.1093/jnci/djk093.
8
Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.在CALGB方案#8935中,N分期降低可预测IIIA期(N2)非小细胞肺癌诱导化疗后的生存率。
J Surg Oncol. 2006 Dec 1;94(7):599-606. doi: 10.1002/jso.20644.
9
Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer.局部晚期非小细胞肺癌患者术前顺铂和多西他赛同步放化疗
Br J Cancer. 2004 Mar 8;90(5):979-84. doi: 10.1038/sj.bjc.6601624.
10
Multidisciplinary management of lung cancer.肺癌的多学科管理
N Engl J Med. 2004 Jan 22;350(4):379-92. doi: 10.1056/NEJMra035536.

多西他赛和顺铂诱导化疗放疗后手术治疗伴有纵隔淋巴结转移的非小细胞肺癌的长期疗效

Long-term outcome of induction chemoradiotherapy with docetaxel and cisplatin followed by surgery for non-small-cell lung cancer with mediastinal lymph node metastasis.

作者信息

Toyooka Shinichi, Kiura Katsuyuki, Takemoto Mitsuhiro, Oto Takahiro, Takigawa Nagio, Fujiwara Toshiyoshi, Miyoshi Shinichiro, Date Hiroshi

机构信息

Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan.

出版信息

Interact Cardiovasc Thorac Surg. 2012 May;14(5):565-9. doi: 10.1093/icvts/ivs028. Epub 2012 Feb 20.

DOI:10.1093/icvts/ivs028
PMID:22354091
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3329306/
Abstract

The purpose of this study was to show the long-term outcome of induction chemoradiotherapy, using docetaxel and cisplatin with concurrent radiotherapy followed by surgery for non-small-cell lung cancer (NSCLC) with mediastinal nodal metastasis. Between January 2000 and July 2006, 22 consecutive NSCLC patients with pathologically proven mediastinal nodal metastasis were treated with tri-modality therapy. The regimen consisted of docetaxel and cisplatin plus concurrent radiation at a dose of 40-46 Gy. The induction therapy was followed by surgery 4-6 weeks later. The pulmonary resections were composed of a lobectomy in 19 patients, including 3 with a sleeve lobectomy, a bilobectomy in 2 patients and a left pneumonectomy in 1 patient. With a median follow-up duration of 8.7 years, the 3-year and 7-year overall survival (OS) rates for the entire population were 72.7 and 63.6%, respectively. Our results suggest that tri-modality therapy is promising for NSCLC patients with mediastinal nodal metastasis.

摘要

本研究的目的是展示多西他赛和顺铂同步放疗后手术治疗非小细胞肺癌(NSCLC)纵隔淋巴结转移的长期疗效。2000年1月至2006年7月,连续22例经病理证实纵隔淋巴结转移的NSCLC患者接受了三联疗法。治疗方案包括多西他赛和顺铂加40-46 Gy的同步放疗。诱导治疗4-6周后进行手术。肺切除术包括19例肺叶切除术,其中3例为袖状肺叶切除术,2例为双叶切除术,1例为左全肺切除术。中位随访时间为8.7年,整个人群的3年和7年总生存率(OS)分别为72.7%和63.6%。我们的结果表明,三联疗法对NSCLC纵隔淋巴结转移患者具有前景。